Cargando…

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile

Omadacycline is a potent aminomethylcycline with in vitro activity against Gram-positive, Gram-negative, and anaerobic bacteria. Preliminary data demonstrated that omadacycline has in vitro activity against Clostridioides difficile; however, large-scale in vitro studies have not been done. The purpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Begum, Khurshida, Bassères, Eugénie, Miranda, Julie, Lancaster, Chris, Gonzales-Luna, Anne J., Carlson, Travis J., Rashid, Tasnuva, Eyre, David W., Wilcox, Mark H., Alam, M. Jahangir, Garey, Kevin W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2020
Materias:	Epidemiology and Surveillance
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526832/ https://www.ncbi.nlm.nih.gov/pubmed/32513796 http://dx.doi.org/10.1128/AAC.00522-20

Ejemplares similares

In vitro activity of eravacycline against common ribotypes of Clostridioides difficile
por: Bassères, Eugénie, et al.
Publicado: (2020)

688. In Vitro Activity of Eravacycline, a New Tetracycline Analog, and Comparators Against the Six Most Commonly Isolated Ribotypes of Clostridioides difficile
por: Basseres, Eugenie, et al.
Publicado: (2019)

Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With Clostridioides difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Assessment of Kidney Injury as a Severity Criteria for Clostridioides Difficile Infection
por: Carlson, Travis J, et al.
Publicado: (2020)

Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence
por: Garey, Kevin W., et al.
Publicado: (2022)

277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
por: Jo, Jinhee, et al.
Publicado: (2023)

Reduced Susceptibility to Metronidazole Is Associated With Initial Clinical Failure in Clostridioides difficile Infection
por: Gonzales-Luna, Anne J, et al.
Publicado: (2021)

1197. Inhibitory Effect of Ursodeoxycholic Acid on Clostridioides difficile Growth
por: Alnezary, Faris, et al.
Publicado: (2020)

784. A Novel Method to Assess Virulence of Clostridioides difficile: Focus on C. difficile Ribotype 106
por: Almutairi, Masaad, et al.
Publicado: (2020)

2398. Effect of Eosinopenia and Binary Toxin on Clostridioides difficile Infection Clinical Outcomes
por: Carlson, Travis J, et al.
Publicado: (2019)

PCR ribotypes of Clostridioides difficile across Texas from 2011 to 2018 including emergence of ribotype 255
por: Gonzales-Luna, Anne J., et al.
Publicado: (2020)

Epidemic Clostridioides difficile Ribotype 027 Lineages: Comparisons of Texas Versus Worldwide Strains
por: Endres, Bradley T, et al.
Publicado: (2019)

2410. Molecular Characteristics of Environmental Clostridioides difficile From a Large Texas Hospital
por: Begum, Khurshida, et al.
Publicado: (2019)

Epidemiology of Clostridioides difficile infections, France, 2010 to 2017
por: Colomb-Cotinat, Mélanie, et al.
Publicado: (2019)

Sentinel surveillance and epidemiology of Clostridioides difficile in Denmark, 2016 to 2019
por: Persson, Søren, et al.
Publicado: (2022)

Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection
por: McPherson, Jacob, et al.
Publicado: (2022)

2391. Increased Risk of Systemic Infections with Multidrug-Resistant Organisms in Patients with Severe Clostridioides difficile Infection
por: Dotson, Kierra M, et al.
Publicado: (2019)

521. Investigating the Gram-Positive Selective Spectrum of Ibezapolstat, a First-in-Class DNA Polymerase IIIC (Pol IIIC) Inhibitor
por: Jahangir Alam, M, et al.
Publicado: (2022)

701. An Open-label Phase 2a Study of Ibezapolstat, a Unique Gram-positive Selective Spectrum (GPSS) Antibiotic, for Patients with Clostridioides difficile Infection
por: Garey, Kevin W, et al.
Publicado: (2021)

Emerging Options for the Prevention and Management of Clostridioides difficile Infection
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

2402. Clinical Outcomes Associated with an Emerging Clostridioides difficile Ribotype 255 in Texas
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

682. Novel rpoB mutations and trends in clinical Clostridioides difficile isolates with reduced fidaxomicin susceptibility
por: Gonzales-Luna, Anne J, et al.
Publicado: (2023)

2063. Elucidating the Gram-Positive Selective Spectrum Activity of Ibezapolstat; Secondary Analysis from the phase 2a trial
por: Lancaster, Chris, et al.
Publicado: (2023)

710. Increased Clinical Failure Rates Associated with Reduced Metronidazole Susceptibility in Clostridioides difficile
por: Gonzales-Luna, Anne, et al.
Publicado: (2018)

741. Antifungal Resistant Candida glabrata Are Most Commonly Colonized in Clostridioides difficile Infection (CDI) Patient Guts in Texas
por: Begum, Khurshida, et al.
Publicado: (2020)

Gut microbiota changes associated with Clostridioides difficile infection and its various treatment strategies
por: Gonzales-Luna, Anne J., et al.
Publicado: (2023)

Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes
por: Madden, Gregory R., et al.
Publicado: (2022)

2581. An Invertebrate Model to Study Gut Microbiome Dysbiosis
por: Alnezary, Faris S, et al.
Publicado: (2019)

Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial( )
por: Garey, Kevin W, et al.
Publicado: (2022)

2580. Serial Microbiome Analysis in a Patient with Multiple Failed Fecal Microbiome Transplantations
por: Gonzales-Luna, Anne J, et al.
Publicado: (2019)

First Environmental Investigation of Toxigenic Clostridium difficile at a Large Hospital in Bangladesh
por: Alam, M Jahangir, et al.
Publicado: (2017)

Comparison of Risk Stratification Approaches to Identify Patients with Clostridioides difficile Infection at Risk for Multidrug-Resistant Organism Gut Microbiota Colonization
por: Zasowski, Evan J., et al.
Publicado: (2023)

661. In vitro Activity of Omadacycline and Comparator Antibiotics against Clostridioides difficile
por: Skinner, Andrew M, et al.
Publicado: (2022)

Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection
por: Bassères, Eugénie, et al.
Publicado: (2016)

Omadacycline: A Modernized Tetracycline
por: Gallagher, Jason C
Publicado: (2019)

1052. Characterisation of the DNA binding properties of ridinilazole, a selective antibiotic currently in phase III trials for the treatment of Clostridioides difficile
por: Mason, Clive, et al.
Publicado: (2021)

2378. Corticosteroid Use Prevents Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use Among Hospitalized Patients
por: Carlson, Travis J, et al.
Publicado: (2019)

471. Prevalence and Characteristics of Clostridioides difficile Infection in Bangladesh
por: Sofjan, Amelia K, et al.
Publicado: (2018)

Corticosteroids Do Not Increase the Likelihood of Primary Clostridioides difficile Infection in the Setting of Broad-Spectrum Antibiotic Use
por: Carlson, Travis J, et al.
Publicado: (2021)

The Novel DNA Binding Mechanism of Ridinilazole, a Precision Clostridiodes difficile Antibiotic
por: Mason, Clive S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_vp8kj9he1e36jja08cmtnl387f